Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression.
Küffner R, Zach N, Norel R, Hawe J, Schoenfeld D, Wang L, Li G, Fang L, Mackey L, Hardiman O, Cudkowicz M, Sherman A, Ertaylan G, Grosse-Wentrup M, Hothorn T, van Ligtenberg J, Macke JH, Meyer T, Schölkopf B, Tran L, Vaughan R, Stolovitzky G, Leitner ML. Küffner R, et al. Among authors: leitner ml. Nat Biotechnol. 2015 Jan;33(1):51-7. doi: 10.1038/nbt.3051. Epub 2014 Nov 2. Nat Biotechnol. 2015. PMID: 25362243
Infrastructure resources for clinical research in amyotrophic lateral sclerosis.
Sherman AV, Gubitz AK, Al-Chalabi A, Bedlack R, Berry J, Conwit R, Harris BT, Horton DK, Kaufmann P, Leitner ML, Miller R, Shefner J, Vonsattel JP, Mitsumoto H. Sherman AV, et al. Among authors: leitner ml. Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14 Suppl 1:53-61. doi: 10.3109/21678421.2013.779058. Amyotroph Lateral Scler Frontotemporal Degener. 2013. PMID: 23678880 Review.
The PRO-ACT database: design, initial analyses, and predictive features.
Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. Atassi N, et al. Neurology. 2014 Nov 4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951. Epub 2014 Oct 8. Neurology. 2014. PMID: 25298304 Free PMC article.
Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?
Zach N, Ennist DL, Taylor AA, Alon H, Sherman A, Kueffner R, Walker J, Sinani E, Katsovskiy I, Cudkowicz M, Leitner ML. Zach N, et al. Among authors: leitner ml. Neurotherapeutics. 2015 Apr;12(2):417-23. doi: 10.1007/s13311-015-0336-z. Neurotherapeutics. 2015. PMID: 25613183 Free PMC article. Review.
Quantitative strength testing in ALS clinical trials.
Shefner JM, Liu D, Leitner ML, Schoenfeld D, Johns DR, Ferguson T, Cudkowicz M. Shefner JM, et al. Among authors: leitner ml. Neurology. 2016 Aug 9;87(6):617-24. doi: 10.1212/WNL.0000000000002941. Epub 2016 Jul 6. Neurology. 2016. PMID: 27385750 Free PMC article. Clinical Trial.
Serum urate at trial entry and ALS progression in EMPOWER.
O'Reilly ÉJ, Liu D, Johns DR, Cudkowicz ME, Paganoni S, Schwarzschild MA, Leitner M, Ascherio A. O'Reilly ÉJ, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):120-125. doi: 10.1080/21678421.2016.1214733. Epub 2016 Sep 28. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 27677562 Free PMC article. Clinical Trial.
Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach.
Kueffner R, Zach N, Bronfeld M, Norel R, Atassi N, Balagurusamy V, Di Camillo B, Chio A, Cudkowicz M, Dillenberger D, Garcia-Garcia J, Hardiman O, Hoff B, Knight J, Leitner ML, Li G, Mangravite L, Norman T, Wang L; ALS Stratification Consortium; Xiao J, Fang WC, Peng J, Yang C, Chang HJ, Stolovitzky G. Kueffner R, et al. Among authors: leitner ml. Sci Rep. 2019 Jan 24;9(1):690. doi: 10.1038/s41598-018-36873-4. Sci Rep. 2019. PMID: 30679616 Free PMC article.
PRO-ACTive sharing of clinical data.
Zach N, Leitner ML. Zach N, et al. Among authors: leitner ml. Nat Biotechnol. 2022 Jul;40(7):999-1000. doi: 10.1038/s41587-022-01395-y. Nat Biotechnol. 2022. PMID: 35778617 No abstract available.
Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.
Writing Committee for the HEALEY ALS Platform Trial; Shefner JM, Oskarsson B, Macklin EA, Chibnik LB, Quintana M, Saville BR, Detry MA, Vestrucci M, Marion J, McGlothlin A, Heiman-Patterson T, Chase M, Pothier L, Harkey BA, Yu H, Sherman AV, Hall M, Kittle G, Berry JD, Babu S, Andrews J, D'Agostino D, Tustison E, Scirocco E, Giacomelli E, Alameda G, Locatelli E, Ho D, Quick A, Ajroud-Driss S, Katz J, Heitzman D, Appel SH, Shroff S, Felice K, Maragakis NJ, Simmons Z, Miller TM, Olney N, Weiss MD, Goutman SA, Fernandes JA, Jawdat O, Owegi MA, Foster LA, Vu T, Ilieva H, Newman DS, Arcila-Londono X, Jackson CE, Ladha S, Caress JB, Swenson A, Peltier A, Lewis RA, Fee D, Elliott M, Bedlack R, Kasarskis EJ, Elman L, Rosenfeld J, Walk D, McIlduff C, Twydell P, Young E, Johnson K, Rezania K, Goyal NA, Cohen JA, Benatar M, Jones V, Shah J, Beydoun SR, Wymer JP, Zilliox L, Nayar S, Pattee GL, Martinez-Thompson J, Leitner ML, Chen K, Goldberg YP, Cohen Y, Geva M, Hayden MR, Paganoni S, Cudkowicz ME; HEALEY ALS Platform Trial Study Group. Writing Committee for the HEALEY ALS Platform Trial, et al. Among authors: leitner ml. JAMA. 2025 Feb 17;333(13):1128-37. doi: 10.1001/jama.2024.26429. Online ahead of print. JAMA. 2025. PMID: 40067755
48 results